BANK VONTOBEL/CALL/ROCHE GS/300/0.02/20.12.24 Stock

Warrant

WROBLV

CH1225162978

Market Closed - Bid/Ask 11:20:00 2024-05-16 EDT Pre-market 02:45:01
0.026 CHF +30.00% Intraday chart for BANK VONTOBEL/CALL/ROCHE GS/300/0.02/20.12.24 0.043 +65.38%
6 months-50.00%
Current year-48.00%
Date Price Change

Delayed Quote Swiss Exchange

Last update May 16, 2024 at 11:20 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WROBLV
ISINCH1225162978
Date issued 2022-11-22
Strike 300 CHF
Maturity 2024-12-20 (214 Days)
Parity 50 : 1
Emission price 0.66 CHF
Emission volume N/A
Settlement physique
Currency CHF

Technical Indicators

Highest since issue 0.73 CHF
Lowest since issue 0.02 CHF
Delta0.09x
Omega 14.23
Premium27.18x
Gearing152.97x
Moneyness 0.7903
Difference Strike 61.9 CHF
Difference Strike %+20.63%
Spread 0.01 CHF
Spread %27.78%
Theoretical value 0.0330
Implied Volatility 21.39 %
Total Loss Probability 92.84 %
Intrinsic value 0.000000
Present value 0.0330
Break even 301.65 CHF
Theta-0x
Vega0.01x
Rho0x

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
237.1 CHF
Average target price
279.4 CHF
Spread / Average Target
+17.84%
Consensus
  1. Stock Market
  2. Warrants
  3. WROBLV Warrant
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW